PTC Therapeutics, Inc. (PTCT) Stock: Price, Forecast & Analyst Target
PTC Therapeutics, Inc. (PTCT) — MoonshotScore 33/100 (Weak band), calculated Oct 26, 2026. Price $61.07 (+0.79%), as of the Oct 26, 2026 trading session; market cap $5.10B. Expected results Oct 29, 2026.
Educational signal · not a buy or sell recommendation · How to read this
Market value / cash and short-term investments: 2.29× (market value Oct 26, 2026; cash Jun 30, 2026) · expected results Oct 29, 2026
PTC Therapeutics, Inc. · PTCT · NASDAQ · Healthcare · Biotechnology
Research dated 2026-09-13: PTC THERAPEUTICS, INC. builds and sells rare-disease medicines, with commercial products such as Translarna, Emflaza, Tegsedi, Waylivra, and Evrysdi, while also running a broader splicing-based R&D program that includes a program for Huntington's disease. Its core question is whether the commercialized rare-disease platform can keep the income base steady while research spending and launch execution move through a high-volatility cycle.
Price as of Oct 26, 2026
Key Statistics
MoonshotScore v2 · PTC Therapeutics (PTCT)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
High quality and elite growth. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and losses on top of negative retained earnings. Business Quality: Elite; Financial Safety: Okay; Valuation: Full; Growth Durability: Compounding; Momentum: Quiet.
- quarterly revenue $361M (Q2 FY2026, quarter ended Jun 30, 2026)
- EPS beat 7 of 8
- Altman Z 0.76 · Piotroski F 2
Helping: business quality, durable growth
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 34 | Weak | |
| 33 | Weak | |
| 33 | Weak | |
| 34 | Weak | |
| 34 | Weak | |
| 33 | Weak |
The score was 33 in the stored Oct 24, 2026 snapshot and remains 33 in the current publication computed Oct 26, 2026 (0); the largest pillar moves were Growth Durability +1 and Momentum -1; the pillar moves offset under the sector-relative weighting, so the headline score is unchanged.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $61.07 | |
| Change on the day | +0.79% | |
| 52-week range | $58.80–$90.87 | |
| Market capitalisation | $5.10B | |
| Price / earnings (trailing) | 26.35 | |
| Shares traded on the day | 708K | |
| Beta (volatility vs the S&P 500) | 0.55 |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings results · below the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings call · management outlook
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
Management outlook
I just want to make clear that we expect this to be, as the launch moves forward into 2027 and beyond, there's many more countries we seek to get to and target that 58,000 global adjustable market.
Matthew Klein · Statement from
As we have previously shared, we expect international revenue to increasingly contribute in late 2026 and into 2027 as additional markets come on board.
Matthew Klein · Statement from
Statement dates identify the earnings call, not a deadline. Management expectations and provider estimates can change.
Read management statementsCouncil Score · weighted blend of 2 available disciplines
Council score for PTC Therapeutics (PTCT): Split View
47/100 · CSome lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
6 lenses, 6 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Oct 26, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
Three of these lenses read this company more favourably than the MoonshotScore does: Dalio-style lens, Klarman-style lens and Moon AI lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
On Sep 9, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 26, 2026, except a card that shows its own read date.
Watch the PTCT film — every key number, told as a short cinematic story
~2 min · open the film
What is PTC Therapeutics (PTCT), and what does it report?
Short answer · as of
This is a commercializing biopharma model, not a pure discovery story. Revenue comes from marketed product sales, royalty economics, and collaboration or license deals, so any quarter in the packet combines operational drug economics with partner-driven income streams.
Research dated 2026-09-13.
This is a commercializing biopharma model, not a pure discovery story. Revenue comes from marketed product sales, royalty economics, and collaboration or license deals, so any quarter in the packet combines operational drug economics with partner-driven income streams.
The reported figures therefore measure two things at once: near-term therapeutic commercialization and the monetization of collaborations and regional rights. The quarterly income statement exposes that split through sales, operating and net outcomes, while the annual summary shows how those pieces scale across a full year.
What do the latest results show for PTC Therapeutics (PTCT)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $361M.
Research dated 2026-09-13.
The latest reported period in the packet is notably profitable at both operating and net level, while the immediately preceding period remained negative on net, so the business has shifted materially in adjacent windows. Sales were also higher than in that prior window, showing growth at the top line that did not require a narrative of lower expense alone.
Management’s communication channel is visible through the periodic filings: the recent quarterly report and related company notices around results and financial condition provide the official context for that change. In the history of reported guidance versus actuals, outcomes have not been one-directional, so a quarter’s surprise does not lock in a trend by itself.
The estimate history also shows both upside and downside deviations, which means the company’s operating cadence is still being read as eventful rather than stable.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
- Latest quarter · revenue
- $360.52M Jun 30, 2026
- Latest quarter · R&D
- $99.15M Jun 30, 2026
- Latest quarter · SG&A
- $80.63M Jun 30, 2026
- Latest quarter · FMP standardized operating result
- $148.98M Jun 30, 2026
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Jun 30, 2026 | $360.52M | $99.15M | $80.63M | $148.98M |
| Mar 31, 2026 | $272.55M | $100.87M | $86.18M | $45.89M |
| Dec 31, 2025 | $164.68M | $133.13M | $100.47M | −$81.62M |
| Sep 30, 2025 | $211.01M | $100.16M | $84.05M | $3.02M |
USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $360.52M Jul 30, 2026
- Latest report · revenue estimate
- $298.63M Jul 30, 2026
- Latest report · revenue vs estimate
- Above estimate Jul 30, 2026
- Latest report · EPS vs estimate
- Above estimate Jul 30, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Jul 30, 2026 | $360.52M | $298.63M | $0.9200 | $0.2363 |
| May 7, 2026 | $272.55M | $217.42M | −$0.0300 | −$0.4500 |
| Feb 19, 2026 | $164.68M | $279.48M | −$1.6700 | −$0.2100 |
| Nov 4, 2025 | $211.01M | $281.45M | $0.2000 | −$1.1900 |
Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $361M | $83M | $0.92 (diluted) |
| Q1 FY2026 | $273M | -$3M | -$0.03 (diluted) |
| Q4 FY2025 | $165M | -$135M | -$1.67 (diluted) |
| Q3 FY2025 | $211M | $16M | $0.20 (diluted) |
What are the financial strengths and risks for PTC Therapeutics (PTCT)?
Short answer
Cash and short-term investments were $2.23B at the Jun 30, 2026 balance-sheet date. Operating cash flow was $129.11M for the quarter ended Jun 30, 2026, meaning operations generated cash. These figures do not establish a cash runway.
Research dated 2026-09-13.
Liquidity is a meaningful strength. Cash and short-term investments sit far above debt, and both short-term solvency ratios are supportive, so immediate refinancing pressure is not the dominant constraint.
The cash trend has moved around in recent windows, and operating cash flow has alternated between replenishing and consuming cash even while capital spending has remained relatively contained, so the business still depends on quarter-by-quarter operating strength to convert that balance-sheet cushion into runway.
The bigger vulnerability is not liquidation risk in isolation but quality-of-income deterioration: trailing metrics still show weak net margin context and weaker screening reads, which can turn a strong cash buffer into a temporary bridge if operating momentum fades.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of 0.76 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
How much cash does the business generate or use?
Quarterly operating cash flow shows cash generated or used by operations.
- Latest quarter · operating cash flow
- $129.11M Jun 30, 2026
- Previous quarter · operating cash flow
- −$59.04M Mar 31, 2026
| Period end | Operating cash flow | Capital expenditure (reported) |
|---|---|---|
| Jun 30, 2026 | $129.11M | −$7.14M |
| Mar 31, 2026 | −$59.04M | −$1.35M |
| Dec 31, 2025 | −$34.27M | −$37.29M |
| Sep 30, 2025 | −$66.30M | −$256.26M |
Operating cash-flow bars share one scale and show magnitude; negative values mean cash used.
USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway.
What should you watch next at PTC Therapeutics (PTCT)?
Short answer · as of
The next earnings report is expected on Oct 29, 2026.
Research dated 2026-09-13.
The nearest check is the next quarterly disclosure, where new revenue and earnings figures arrive against existing expectations. That date is already in the filing path, so watch for whether execution keeps the current positive sequence intact.
The concrete test is two-part: whether operational profit and net results hold, and whether operating cash flow stays constructive instead of reverting to a burn phase.
Given prior episodes where reported results moved both above and below expectations, the next read is best treated as an execution signal, not a narrative reset by itself.
What management is planning
Management expectations, not completed milestones or guarantees. Selected verbatim excerpts; dates follow the transcript provider.
I just want to make clear that we expect this to be, as the launch moves forward into 2027 and beyond, there's many more countries we seek to get to and target that 58,000 global adjustable market.
Matthew Klein ·
As we have previously shared, we expect international revenue to increasingly contribute in late 2026 and into 2027 as additional markets come on board.
Matthew Klein ·
While the U.S. remains an important near-term growth driver, we expect global revenue to become an increasingly meaningful contributor in the second half of this year and well into 2027. As we discussed, there is a large addressable PKU population globally in markets where innovative treatments are reimbursed, we expect to bring Sephience to as many of these countries as quickly as possible, reinforcing our confidence in achieving a multi-billion dollar peak revenue potential.
Eric Pauwels ·
How does PTC Therapeutics compare with its peers?
Short answer
PTC Therapeutics's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13.
Many rare-disease peers focus on research plus a narrow commercial output, but this company has a distinct footprint with multiple marketed medicines, broad regional commercialization, and explicit royalty and license dependence. That changes the valuation engine from pure pipeline optionality to a blend of access, reimbursement, and contract economics.
Partnership links with large pharmaceutical groups and regional collaborators are therefore not background detail; they are structural to how PTC turns research discoveries into geography-specific revenue streams. If one route stalls, another channel can still support activity, but the reverse is also true when access or partner execution weakens.
| Company | Price | Market value | Score |
|---|---|---|---|
| $313.66 Oct 26, 2026 | $9.26B | 98 5-pillar Oct 26, 2026 | |
| $308.30 Oct 26, 2026 | $6.05B | 96 5-pillar Oct 26, 2026 | |
| $48.20 Oct 26, 2026 | $3.85B | 96 5-pillar Oct 26, 2026 | |
| $43.74 Oct 26, 2026 | $3.92B | 95 5-pillar Oct 26, 2026 | |
| $31.81 Oct 26, 2026 | $3.92B | 92 5-pillar Oct 26, 2026 | |
| $143.35 Oct 26, 2026 | $5.77B | 68 5-pillar Oct 26, 2026 | |
| $54.79 Oct 26, 2026 | $8.39B | 67 5-pillar Oct 26, 2026 | |
| $44.44 Oct 26, 2026 | $7.46B | 66 5-pillar Oct 26, 2026 | |
| $137.39 Oct 26, 2026 | $5.74B | 66 5-pillar Oct 26, 2026 | |
| $90.33 Oct 26, 2026 | $5.98B | 66 5-pillar Oct 26, 2026 | |
| $39.17 Oct 26, 2026 | $4.21B | 65 5-pillar Oct 26, 2026 | |
| $27.09 Oct 26, 2026 | $3.41B | 64 5-pillar Oct 26, 2026 | |
| PTC Therapeutics (PTCT) — this page | $61.07 | $5.10B | 33 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $75.00 – $137.00
- Consensus target
- $102.89
- Median target
- $104.00
Consensus record · Captured .
Measured against a quoted price of $61.07 (as of Oct 26, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Oct 14, 2026
- Transactions
- 92
- Identified insiders
- 8
- Purchases
- 0
- Sales
- 52
- Other transactions
- 40
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
- Reporting holders
- 392 Period end Jun 30, 2026
- Previous quarter · holders
- 362 Prior to period end Jun 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Blackrock, INC. | 13,964,554 |
| Rtw Investments, LP | 7,746,415 |
| Jupiter Topco LLC | 7,236,402 |
| Vanguard Portfolio Management LLC | 4,928,111 |
| State Street Corp | 4,598,952 |
Quarterly filings lag the period end. Holder rows are names in the provider snapshot, not a verified ranking; individual filing dates are not supplied. Related managers may appear separately, so these positions are not summed. Holder snapshot as of Jun 30, 2026.
What has been published about PTC Therapeutics (PTCT)?
- Analysts Estimate PTC Therapeutics (PTCT) to Report a Decline in Earnings: What to Look Out for
- PTC Therapeutics (NASDAQ:PTCT) Director Sells $149,025.00 in Stock
- UBS Adjusts Price Target on PTC Therapeutics to $90 From $80, Maintains Buy Rating
- PTC Therapeutics to Report Third Quarter 2026 Financial Results on Thursday, Oct. 29, 2026
What Investors Ask About PTC Therapeutics (PTCT) — Healthcare
Research dated 2026-09-13; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
Which PTCT therapies and indications are tied to specific regions in the business model?
PTC sells Translarna and Emflaza into Duchenne muscular dystrophy use cases in core regions, with Translarna also reaching additional markets for the nonsense mutation form. Tegsedi and Waylivra are commercialized in Latin America and the Caribbean profile, while Evrysdi is part of the Brazil footprint for pediatric spinal muscular atrophy treatment.
Why does PTCT’s profitability swing so much from one reporting period to the next?
The core cause is visible in the structure itself: commercial sales can be volatile while R&D and commercial overhead remain substantial, and operating results flow directly from that mix. Operating cash flow confirms the same pattern by showing both positive and negative quarters over the recent run. Because of that, one strong quarter does not eliminate near-term downside in the next window.
How long does PTCT’s liquidity story really last if operations cool off?
The company has a large liquid reserve base and a meaningful gap over short-term liabilities, which supports flexibility if commercial timing slips. The condition becomes fragile only when that liquidity is tested by repeated operating cash weakness, since cash history already shows meaningful movement in both directions. That is why the next few quarters matter: funding confidence depends on preserving the cushion while recurring spend stays aligned with execution.
What does ownership activity suggest about near-term pressure on PTCT governance and control?
Institutional presence is broad and includes multiple large holders, so the ownership base is not concentrated in a narrow few. The latest insider activity window, however, was dominated by outbound or non-purchase flows rather than fresh insider buying, which can add interpretive pressure even when it does not by itself change fundamentals. So ownership is stable in breadth, but the composition of insider flow is one of the early signals to monitor.
What is the PTCT stock price today?
The last price recorded on this page for PTC Therapeutics, Inc. (PTCT) is $61.07, as of the Oct 26, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the PTCT price target?
The analyst consensus price target for PTC Therapeutics, Inc. (PTCT) is $102.89 (range $75.00 to $137.00, median $104.00), per FMP data captured Oct 26, 2026. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Research written by Codex (gpt-5.3-codex-spark) on 2026-09-13. AI-authored analysis; source dates are shown with each answer. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (81 figures)
The 81 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
OFFICIAL — 2 facts from SEC filings and earnings calls
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
prod.outlook | Management outlook — call excerpts | Matthew Klein (Jul 30, 2026): I just want to make clear that we expect this to be, as the launch moves forward into 2027 and beyond, there's many more countries we seek to get to and target that 58,000 global adjustable market. Matthew Klein (Jul 30, 2026): As we have previously shared, we expect international revenue to increasingly contribute in late 2026 and into 2027 as additional markets come on board. Eric Pauwels (Jul 30, 2026): While the U.S. remains an important near-term growth driver, we expect global revenue to become an increasingly meaningful contributor in the second half of this year and well into 2027. As we discussed, there is a large addressable PKU population globally in markets where innovative treatments are reimbursed, we expect to bring Sephience to as many of these countries as quickly as possible, reinforcing our confidence in achieving a multi-billion dollar peak revenue potential. | OFFICIAL | Company earnings call, transcript via Financial Modeling Prep (FMP) — Selected verbatim statements from the latest available call, dated by the transcript provider. Management expectations, not completed milestones or guarantees. Relative dates retain the speaker's wording. | |
id.hq | SEC filing business address | Warren, NJ | OFFICIAL | SEC EDGAR filer business address — The SEC filer business address. Our market-data provider separately lists "500 Warren Corporate Center Drive, Warren, NJ, 07059, US". The FMP company description names South Plainfield, New Jersey as the headquarters; this page uses the address in this row. |
FMP — 72 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.next | Next earnings date | Oct 29, 2026 | FMP | Financial Modeling Prep (FMP) earnings calendar — The date is our provider's estimate until the company confirms it. | |
px.last | Latest provided price | $61.07 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-26T20:00:01.000Z. | |
px.change | Change on the day | +0.79% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $5.10B | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-26. FMP quote timestamp: 2026-10-26T20:00:01.000Z. Captured from FMP at 2026-10-26T22:56:56.745Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
px.change_abs | Change on the day, in dollars | +$0.48 | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q2 FY2026 | $361M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
px.range52 | 52-week range | $58.80–$90.87 | FMP | Financial Modeling Prep (FMP) quote | |
px.pe | Price / earnings (trailing) | 26.35 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 708K | FMP | Financial Modeling Prep (FMP) · quote | |
px.beta | Beta | 0.55 | FMP | Financial Modeling Prep (FMP) company profile | |
id.ceo | Chief executive | Matthew Klein | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
id.founder | Founder named in the filing | Allan Steven Jacobson — Co-Founder & Independent Director | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
id.employees | Employees | 991 | FMP | Financial Modeling Prep (FMP) employee count, from the company's filing | |
fin.annual | Revenue and net result by fiscal year | 5 fiscal years, FY2021 through FY2025: FY2021 revenue $538.59M, net result −$523.90M; FY2022 revenue $698.80M, net result −$559.02M; FY2023 revenue $937.82M, net result −$626.60M; FY2024 revenue $806.78M, net result −$363.29M; FY2025 revenue $1.73B, net result $682.64M | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements | |
fin.rev_mix | Reported revenue segments | Product $586.70M · Royalty $244.22M · Collaboration and License Revenue $998.36M | FMP | Financial Modeling Prep (FMP) revenue segmentation, from the company's 10-K | |
fin.gross_margin | Gross margin (trailing twelve months) | 82.1% | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
fin.q_table.depth.2026-06-30.revenue_k | Revenue — period end 2026-06-30 | $360.52M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.rd_k | R&D — period end 2026-06-30 | $99.15M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.sga_k | SG&A — period end 2026-06-30 | $80.63M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.operating_result_k | FMP standardized operating result — period end 2026-06-30 | $148.98M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.revenue_k | Revenue — period end 2026-03-31 | $272.55M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.rd_k | R&D — period end 2026-03-31 | $100.87M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.sga_k | SG&A — period end 2026-03-31 | $86.18M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.operating_result_k | FMP standardized operating result — period end 2026-03-31 | $45.89M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.revenue_k | Revenue — period end 2025-12-31 | $164.68M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.rd_k | R&D — period end 2025-12-31 | $133.13M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.sga_k | SG&A — period end 2025-12-31 | $100.47M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.operating_result_k | FMP standardized operating result — period end 2025-12-31 | −$81.62M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.revenue_k | Revenue — period end 2025-09-30 | $211.01M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.rd_k | R&D — period end 2025-09-30 | $100.16M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.sga_k | SG&A — period end 2025-09-30 | $84.05M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.operating_result_k | FMP standardized operating result — period end 2025-09-30 | $3.02M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
earn.history.depth.2026-07-30.revenue_actual | Revenue · reported — report date 2026-07-30 | $360.52M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-07-30.revenue_estimated | Revenue · estimate — report date 2026-07-30 | $298.63M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-07-30.eps_actual | EPS · reported — report date 2026-07-30 | $0.9200 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-07-30.eps_estimated | EPS · estimate — report date 2026-07-30 | $0.2363 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-07.revenue_actual | Revenue · reported — report date 2026-05-07 | $272.55M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-07.revenue_estimated | Revenue · estimate — report date 2026-05-07 | $217.42M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-07.eps_actual | EPS · reported — report date 2026-05-07 | −$0.0300 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-07.eps_estimated | EPS · estimate — report date 2026-05-07 | −$0.4500 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-19.revenue_actual | Revenue · reported — report date 2026-02-19 | $164.68M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-19.revenue_estimated | Revenue · estimate — report date 2026-02-19 | $279.48M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-19.eps_actual | EPS · reported — report date 2026-02-19 | −$1.6700 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-19.eps_estimated | EPS · estimate — report date 2026-02-19 | −$0.2100 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-04.revenue_actual | Revenue · reported — report date 2025-11-04 | $211.01M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-04.revenue_estimated | Revenue · estimate — report date 2025-11-04 | $281.45M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-04.eps_actual | EPS · reported — report date 2025-11-04 | $0.2000 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-04.eps_estimated | EPS · estimate — report date 2025-11-04 | −$1.1900 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
fin.cash_investments | Cash and short-term investments | $2.23B | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. | |
fin.opcf_latest | Latest-quarter operating cash flow | $129.11M | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Period end: 2026-06-30. Negative operating cash flow means cash used. This figure is not a cash-runway estimate. | |
fin.long_term_investments | Long-term investments (classification unverified) | $0.00 | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.total_debt | Total debt | $696.47M | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.opcf.depth.2026-06-30.operating_cash_flow_m | Operating cash flow — period end 2026-06-30 | $129.11M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-03-31.operating_cash_flow_m | Operating cash flow — period end 2026-03-31 | −$59.04M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-06-30.capex_m | Capital expenditure (reported) — period end 2026-06-30 | −$7.14M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-03-31.capex_m | Capital expenditure (reported) — period end 2026-03-31 | −$1.35M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-12-31.operating_cash_flow_m | Operating cash flow — period end 2025-12-31 | −$34.27M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-12-31.capex_m | Capital expenditure (reported) — period end 2025-12-31 | −$37.29M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-09-30.operating_cash_flow_m | Operating cash flow — period end 2025-09-30 | −$66.30M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-09-30.capex_m | Capital expenditure (reported) — period end 2025-09-30 | −$256.26M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
earn.pt_range | Analyst price target, low to high | $75.00 – $137.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 26, 2026 · Coverage not supplied | |
earn.pt_consensus | Consensus analyst price target | $102.89 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 26, 2026 · Coverage not supplied | |
earn.pt_median | Median analyst price target | $104.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 26, 2026 · Coverage not supplied | |
own.insiders | Insider transactions via FMP | 92 transactions · 0 purchases, 52 sales, 40 other transactions · 8 identified insiders · of the newest 100 records, those within the last 180 days, newest dated Oct 14, 2026 | FMP | Financial Modeling Prep (FMP), carrying Form 4 transaction records — Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent. | |
own.institutions.depth.holders | Reporting holders | 392 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.holders_previous_quarter | Previous quarter · holders | 362 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.top_holders.depth.holder_0.shares | Blackrock, INC. — shares in provider snapshot | 13,964,554 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_1.shares | Rtw Investments, LP — shares in provider snapshot | 7,746,415 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_2.shares | Jupiter Topco LLC — shares in provider snapshot | 7,236,402 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_3.shares | Vanguard Portfolio Management LLC — shares in provider snapshot | 4,928,111 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_4.shares | State Street Corp — shares in provider snapshot | 4,598,952 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. |
UNRECORDED — 2 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.history | Reported versus estimated, recent quarters | EPS beat 7 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-10-20 · Expired observation | |
fin.scores | Distress and quality screens | Altman Z 0.76 · Piotroski F 2 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-24 · Expired observation |
COMPUTED — 3 facts from our arithmetic, formula restated
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
fin.mcap_to_cash | Market value per dollar of cash and short-term investments | 2.29× | — | COMPUTED | Computed on this page from the figures above — The market capitalisation printed on this page divided by cash and short-term investments of $2.23B at Jun 30, 2026. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. Market cap record date: 2026-10-26. Balance-sheet reference date: 2026-06-30. The inputs do not establish a single common source date for this ratio. |
earn.history.depth.2026-07-30.revenue_actual.comparison | Latest report · revenue vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported revenue ($360.52M) with the recorded estimate ($298.63M) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
earn.history.depth.2026-07-30.eps_actual.comparison | Latest report · EPS vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported EPS ($0.9200) with the recorded estimate ($0.2363) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
OURS — 2 facts from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
ours.moonshot | MoonshotScore v2 | 33 of 100 · Weak · pillars 81 / 52 / 53 / 91 / 51 | OURS | Stock Expert AI MoonshotScore v2 engine | |
ours.moonshot_change | MoonshotScore movement | 33 (stored snapshot Oct 24, 2026) → 33 (current publication computed Oct 26, 2026) (0) | OURS | Stock Expert AI current score publication and immutable score snapshots |
Fact-family notes
- Quarterly statement note. Source series as of 2026-06-30. USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow. Applies to Fact IDs:
fin.q_table.depth.2026-06-30.revenue_k,fin.q_table.depth.2026-06-30.rd_k,fin.q_table.depth.2026-06-30.sga_k,fin.q_table.depth.2026-06-30.operating_result_k,fin.q_table.depth.2026-03-31.revenue_k,fin.q_table.depth.2026-03-31.rd_k,fin.q_table.depth.2026-03-31.sga_k,fin.q_table.depth.2026-03-31.operating_result_k,fin.q_table.depth.2025-12-31.revenue_k,fin.q_table.depth.2025-12-31.rd_k,fin.q_table.depth.2025-12-31.sga_k,fin.q_table.depth.2025-12-31.operating_result_k,fin.q_table.depth.2025-09-30.revenue_k,fin.q_table.depth.2025-09-30.rd_k,fin.q_table.depth.2025-09-30.sga_k,fin.q_table.depth.2025-09-30.operating_result_k. - Earnings-history note. Source series as of 2026-07-30. Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined. Applies to Fact IDs:
earn.history.depth.2026-07-30.revenue_actual,earn.history.depth.2026-07-30.revenue_estimated,earn.history.depth.2026-07-30.revenue_actual.comparison,earn.history.depth.2026-07-30.eps_actual.comparison,earn.history.depth.2026-07-30.eps_actual,earn.history.depth.2026-07-30.eps_estimated,earn.history.depth.2026-05-07.revenue_actual,earn.history.depth.2026-05-07.revenue_estimated,earn.history.depth.2026-05-07.eps_actual,earn.history.depth.2026-05-07.eps_estimated,earn.history.depth.2026-02-19.revenue_actual,earn.history.depth.2026-02-19.revenue_estimated,earn.history.depth.2026-02-19.eps_actual,earn.history.depth.2026-02-19.eps_estimated,earn.history.depth.2025-11-04.revenue_actual,earn.history.depth.2025-11-04.revenue_estimated,earn.history.depth.2025-11-04.eps_actual,earn.history.depth.2025-11-04.eps_estimated. - Cash-flow note. Source series as of 2026-06-30. USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway. Applies to Fact IDs:
fin.opcf.depth.2026-06-30.operating_cash_flow_m,fin.opcf.depth.2026-03-31.operating_cash_flow_m,fin.opcf.depth.2026-06-30.capex_m,fin.opcf.depth.2026-03-31.capex_m,fin.opcf.depth.2025-12-31.operating_cash_flow_m,fin.opcf.depth.2025-12-31.capex_m,fin.opcf.depth.2025-09-30.operating_cash_flow_m,fin.opcf.depth.2025-09-30.capex_m.
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources used for research written 2026-09-13
Historical evidence preserved with this analysis. Current figures are listed separately above.
| Evidence | Captured value | Source date | Source type | Source |
|---|---|---|---|---|
| Legal name | PTC THERAPEUTICS, INC. Our market-data provider lists the name as "PTC Therapeutics, Inc."; the filer's own record is used here. | 2026-02-19 | OFFICIAL | SEC EDGAR — 10-K filed 2026-02-19 |
| Business description | PTC Therapeutics, Inc. (PTCT) is a biopharmaceutical company committed to the research, development, and commercialization of innovative therapies for patients afflicted with rare genetic disorders. Its robust pipeline encompasses both commercialized therapies and a variety of experimental drug candidates, spanning all stages of development—from early research and preclinical studies to clinical trials—with a primary focus on addressing various rare disease indications. Among its commercialized products, PTC Therapeutics provides Translarna and Emflaza, offering therapeutic options for Duchenne muscular dystrophy patients in the European Economic Area and the United States. Translarna also addresses nonsense mutation Duchenne muscular dystrophy in Brazil and Russia. The company additionally commercializes Tegsedi and Waylivra for various rare conditions throughout Latin America and the Caribbean. Furthermore, in Brazil, PTC Therapeutics distributes Evrysdi as a treatment for spinal muscular atrophy (SMA) in patients aged two months and older. Leveraging its proprietary splicing platform, the company is also actively developing PTC518, a promising therapeutic candidate aimed at treating Huntington's disease. To bolster its research and development capabilities, PTC Therapeutics has established strategic collaborations, including partnerships with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation, focusing on advancing drug discovery and development research, particularly in regenerative medicine. Additionally, it collaborates with Akcea Therapeutics, Inc. for the commercialization of Tegsedi and Waylivra in the Latin America and Caribbean region. Established in 1998, PTC Therapeutics, Inc. maintains its corporate headquarters in South Plainfield, New Jersey. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) company profile |
| Revenue by segment | Product: $586.70M; Royalty: $244.22M; Collaboration and License Revenue: $998.36M | 2025-12-31 | FMP | Financial Modeling Prep (FMP) revenue segmentation, from the company's 10-K |
| Sector / industry (provider taxonomy) | Healthcare / Biotechnology The company's SEC filings classify it under SIC 2834 — Pharmaceutical Preparations. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) company profile |
| Quarterly income statement (USD thousands) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements |
| Annual revenue and net result (USD millions) | Captured record · 5 entries
| 2025-12-31 | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements |
| Reported versus estimated, last 8 quarters | Captured record · 8 entries
| 2026-07-30 | FMP | Financial Modeling Prep (FMP) earnings |
| Most recent periodic reports | 2026-07-30 | OFFICIAL | SEC EDGAR filer submissions | |
| Recent SEC filings |
| 2026-08-28 | OFFICIAL | SEC EDGAR filer submissions |
| Next earnings report | Date: 2026-11-03; EPS estimate: $0.2755 per share; Revenue estimate: $302.32M The date is our provider's estimate until the company confirms it. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) earnings calendar |
| Cash, investments and debt | Total debt: $696.47M; Liquidity basis: cash and short-term investments; Total liabilities: $3.42B; Cash and short-term investments: $2.23B; Cash and investments: $2.23B; Long-term investments: $0; Long-term investments classification: unclassified Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's balance sheet |
| Cash and short-term investments over time (USD millions) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's quarterly balance sheets |
| Operating cash flow by quarter (USD millions) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements |
| Trailing twelve-month ratio set | Quick ratio: 3.28; Current ratio: 3.39; Debt to equity: -4.21; Net margin: -3.8%; Gross margin: 82.1%; Operating margin: 11.5%; Return on assets: -1.2%; Return on equity: 21.7% Price-based multiples captured at research time are not repeated here; the page shows each once, from current figures with their own dates. A ratio our provider could not compute is absent rather than shown as zero. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm |
| Cash against market value | As of: 2026-06-30; Cash basis: cash and short-term investments; Net cash: $1.53B; Total debt: $696.50M; Cash and investments: $2.23B Price-based multiples captured at research time are not repeated here; the page shows each once, from current figures with their own dates. Cash is the latest reported cash and short-term investment balance; long-term investments are excluded. Market capitalization is the latest provider value.; The reported balance does not establish unrestricted availability or liquidation value.; The two are measured on different dates — the balance sheet is a quarter-end, the market cap is a recent close.; Debt is total debt as reported, including operating lease liabilities where the filer includes them. | 2026-06-30 | COMPUTED | Computed from the balance sheet and the latest market capitalization |
| Distress and quality screens | Altman Z-score: 0.84; Piotroski F-score: 2 Altman Z below 1.8 is the conventional distress zone. The screen is built for manufacturers and industrials; for banks, insurers and property companies it is not a meaningful reading. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) financial scores |
| SEC filing business address | 500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ, 07059 The SEC filer business address. Our market-data provider separately lists "500 Warren Corporate Center Drive, Warren, NJ, 07059, US". | 2026-09-13 | OFFICIAL | SEC EDGAR filer business address |
| Institutional ownership (13F) | Holders: 392; Quarter: 2026-06-30; Holders previous quarter: 362 13F filings are quarterly and lag the quarter end by up to 45 days. | 2026-06-30 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings |
| Largest 5 institutional holders | Captured record · 5 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings |
| Insider transactions, last 180 days | Net shares: -78,122; Window days: 180; Price low: $25.69; Price high: $90.25; Buy transactions: 0; Distinct insiders: 7; Sell transactions: 33; Other transactions: 19; Total transactions: 52; Other transaction types: A-Award: 4, M-Exempt: 15; Unknown direction transactions: 0 Purchase and sale counts require explicit provider transaction types, without a conflicting acquisition/disposition direction. Other transactions retain their provider type; awards, exercises, gifts and in-kind transactions are not counted as purchases or sales. Net shares sums acquired minus disposed shares across direction-known records, including other transaction types; unknown directions are excluded. It is not net purchases or a verified change in beneficial ownership. Named-insider counts, same-day clusters and positive reported prices cover all retained records. Filing dates are used only when transaction dates are absent. Neither timing nor price establishes motive or whether a transaction was on the open market. | 2026-09-10 | FMP | Financial Modeling Prep (FMP) insider transactions, from Form 4 filings |
Data provided for informational purposes only.
ETFs that hold PTCT
Funds in our ETF coverage that list PTCT among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| iShares Neuroscience and Healthcare ETF (IBRN) | 3.64% |